Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03542877 · ClinicalTrials.gov registry record · Phase 2
Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
A Phase 2 study of Colorectal Cancer, sponsored by Academic Thoracic Oncology Medical Investigators Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 10
- Study locations
NCT03542877: Completed Phase 2 study of Colorectal Cancer, sponsored by Academic Thoracic Oncology Medical Investigators Consortium.
NCT03542877 is a Phase 2 study of Colorectal Cancer that has completed, run by Academic Thoracic Oncology Medical Investigators Consortium. The registered enrollment target is 44 participants, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03542877, a Phase 2 study of Colorectal Cancer, has completed, sponsored by Academic Thoracic Oncology Medical Investigators Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study seeks to use Cabozantinib to treat those with Metastatic Colorectal Cancer who have not previously responded to treatment.
Primary Outcome
A patient is classified as progression-free if s/he is assessed as not having progressive disease (PD) as defined per RECIST 1.1 criteria at either the 12-week assessment or after having at least 11 weeks of treatment for subjects without the 12-week assessment. Censored patients (i.e. those who have not progressed but who are missing a 12-week assessment) are not included in the analysis. Subjects who didn't have the 12-week assessment but who had clinical progression were included and consider
Conditions Studied
Interventions
- DRUG Oral Tablet: Cabozantinib
Study Locations (10)
Pennsylvania
- Jefferson Abington Hospital - Abington
- Thomas Jefferson University - Philadelphia
- Fox Chase Cancer Center - Philadelphia
Colorado
- Universtiy of Colorado Denver - Aurora
- Lone Tree Health Center - Lone Tree
Arizona
- University of Arizona - Tucson
California
- Kenneth Norris Jr. Comprehensive Cancer Center - Los Angeles
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Washington
- Swedish Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2022-03-07 |
| Phase | Phase 2 |
What the finished NCT03542877 record still lists
NCT03542877 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Oral Tablet: Cabozantinib is the first listed.
NCT03542877 lists 10 locations in 7 states (Pennsylvania, Colorado, Arizona).
Frequently Asked Questions
What is clinical trial NCT03542877 about?
NCT03542877 is a clinical study titled "Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer". This study seeks to use Cabozantinib to treat those with Metastatic Colorectal Cancer who have not previously responded to treatment.
What is the current status of trial NCT03542877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2018-06-01. Estimated completion is 2022-03-07.
What conditions does trial NCT03542877 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT03542877?
The interventions under investigation include: Oral Tablet: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT03542877?
This trial is sponsored by Academic Thoracic Oncology Medical Investigators Consortium, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03542877 being conducted?
This trial has 10 study locations across Arizona, California, Colorado, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03542877's enrollment target sits among peer trials
44 287th of 381 higher than 92 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI